Position in LFCR
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$467,790
-$209,464 QoQ
Shares Held
125,750
+51.9% QoQ
Ownership
0.335%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2020
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LFCR Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026GSA CAPITAL PARTNERS LLP holds $10,668,998 across 16 Drug Manufacturers - Specialty & Generic names. LFCR ranks #11 (4.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IRWD |
Ironwood Pharmaceuticals Inc
|
654,445 | $2,297,101 | |
| 2 | LQDA |
Liquidia Corp
|
35,406 | $1,336,222 | |
| 3 | VTRS |
Viatris Inc
|
89,952 | $1,215,251 | |
| 4 | NBIX |
Neurocrine Biosciences Inc
|
6,688 | $881,077 | |
| 5 | RGC |
Regencell Bioscience Holdings Ltd
|
31,569 | $802,799 | |
| 6 | SCYX |
Scynexis Inc
|
87,542 | $642,208 | |
| 7 | XERS |
Xeris Biopharma Holdings, Inc.
|
101,438 | $588,340 | |
| 8 | SUPN |
Supernus Pharmaceuticals, Inc.
|
10,556 | $545,639 |
All Filings in LFCR
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $467,790 | 125,750 | Shares | Sole | 2026-05-08 | |
| 2025-12-31 | $677,254 | 82,794 | Shares | Sole | 2026-02-06 | |
| 2022-12-31 | $129,379 | 19,966 | Shares | Sole | 2023-02-13 | |
| 2022-09-30 | $136,994 | 15,410 | Shares | Sole | 2022-11-14 | |
| 2021-09-30 | $370,210 | 40,153 | Shares | Sole | 2021-11-12 | |
| 2020-12-31 | $256,125 | 23,606 | Shares | Sole | 2021-02-03 | |
| 2020-09-30 | $465,967 | 47,939 | Shares | Sole | 2020-11-06 | |
| 2020-06-30 | $116,247 | 14,604 | Shares | Sole | 2020-08-11 | |
| No filing history on record for this holder in this stock. | ||||||